AccuLine

We're happy to announce that AccuLine has been selected to present at LSI Europe 24, Medtech’s premier partnering event this September! Attending #LSIEurope24? Connect with Our CEO, Moshe Barel and explore how we can shape the future of healthcare together! 

🫀 Understanding Coronary Artery Disease🫀 Coronary Artery Disease (CAD) remains a leading cause of mortality worldwide, yet many people are unaware of its causes, symptoms, and preventive measures. Empower yourself with the knowledge to safeguard your heart health. Review the deck below to take the first step towards a healthier future.

We are thrilled to announce that we have reached 2,000 followers on LinkedIn! Thank you to each and every one of you for your continued support and engagement. We're excited to keep sharing our journey with you and look forward to even more growth and success in the future. Stay tuned for exciting updates, insights, and opportunities. 

We're pleased to share that AccuLine was recently reviewed by CTech by Calcalist regarding our successful seed round. You can read the full review in the first comment.

We are thrilled to welcome Tamar Reitich-Stolero Ph.D. as Director of Data Science at AccuLine! 🎉   Tamar brings over eight years of research experience in machine learning and data science, making her a phenomenal addition to our team. With a distinguished background from the Weizmann Institute of Science and Tel Aviv Medical Center, she has conducted groundbreaking research on the neural basis of learning and decision-making. Her expertise spans data manipulation and modeling, advanced tools like signal processing, statistical inference, and both supervised and unsupervised learning.   In addition to her research accomplishments, Tamar has mentored graduate students and taught a graduate-level statistics course at the Weizmann Institute, demonstrating her commitment to education and mentorship.   At AccuLine, Tamar will play a pivotal role in leveraging machine learning models to predict CAD, harnessing her extensive knowledge and experience to drive our data science initiatives forward.   Please join us in giving a warm welcome to Tamar! We are excited to see the incredible contributions she will make to our team and the innovative projects she will lead.

Exciting Times at SelectUSA 2024! This week I attended the Select USA 2024 conference in Washington DC, representing AccuLine as part of the Israeli delegation of companies. This event is a significant milestone for us as we bring CORA, our innovative system for the early detection of coronary artery disease, closer to the US market. With all 50 states represented at the conference, we had the chance to meet and discuss potential collaborations and opportunities for AccuLine in the US. The conference was a hub of insightful panels and discussions tailored for companies like ours interested in establishing a presence in the US. We had keynote talks from several U.S. cabinet members, including Secretary of State Antony Blinken. Additionally, we enjoyed a wonderful evening hosted by the Embassy of Israel to the United States with Israeli Ambassador Michael Herzog at the Chamber of Commerce in D.C. We attended another great event at the Nationals Park, hosted by the Washington DC Economic Partnership. Lastly, we had a productive visit to the The National Institutes of Health (NIH), where we presented our technology and learned about the opportunities the NIH can offer. A huge thank you to everyone who helped organize this delegation and make our participation possible, especially Sigal Mendelovich and Adi Haliva-Klein.

We presented today at the Biomed Israel 2024 meeting. This event provided a valuable platform to showcase our CORA system, which uses AI-driven signal processing for the early detection of coronary artery disease. Our participation emphasized our commitment to prevent heart attacks through innovative, non-invasive diagnostic solutions. We were thrilled by the significant interest and enthusiasm from potential partners and industry leaders. The interactions and discussions at the conference were invaluable, offering numerous opportunities for future collaborations and advancements in medical technology. We look forward to building on the momentum generated at Biomed Israel.

We are thrilled to announce that AccuLine was accepted to Google AI Startups Fund! Google has recently launched a $4 million fund, in collaboration with the Israeli Innovation Authority, specifically designed to accelerate the growth of promising AI startups. The grant we receive from Google, will serve as a catalyst for our business, enabling us to maintain ambitious goals and plans forward.

🌟 Exciting News! 🌟 We're absolutely delighted to announce a significant addition to our Scientific Advisory Board - Dr. Thomas D. Thacher. Dr. Thacher, MD, holds the distinguished position of Parker D. Sanders and Isabella G. Sanders Professor of Family Medicine at the prestigious Mayo Clinic in Rochester, Minnesota. With an active practice encompassing both outpatient and inpatient care, Dr. Thacher brings a wealth of clinical experience to our board. His commitment to patient care is exemplary, evident in his dedication to training Family Medicine residents and medical students. Beyond clinical practice, Dr. Thacher is a trailblazer in research, particularly in the realm of implementing AI innovations in primary care. With over 130 medical journal publications to his name, his contributions to advancing medical knowledge are substantial. Within the Mayo Clinic, Dr. Thacher serves as the Vice-Chair of Research in Family Medicine, a testament to his leadership and dedication to fostering research excellence. He has also played pivotal roles, serving as the Chair of the Mayo Clinic Quality Review Board and as a valued member of the Editorial Board of the Mayo Clinic Proceedings journal. Dr. Thacher's expertise and leadership will undoubtedly enrich our endeavors as we strive to revolutionize early detection of CAD. We're immensely honored to welcome him to our team and eagerly anticipate the invaluable insights and guidance he'll provide.